Cardiovascular Sequel in Type-2 Diabetes Mellitus Patients on Various Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systemic Review and Meta-Analysis. [PDF]
CureusPrakash V, Goel N.
europepmc +1 more source
Treatment preference for once-weekly versus once-daily DPP-4 inhibitors in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. [PDF]
Ann MedXie X, Chen Y, Wang P, Hu M.
europepmc +1 more source
Dipeptidyl peptidase-4 and kidney fibrosis in diabetes [PDF]
, 2016 Daisuke Koya, Keizo Kanasaki, Sen Shi
core +1 more source
Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease? [PDF]
, 2015 core +1 more source
Association of DPP-4 inhibitors with respiratory and cardiovascular complications in patients with COPD: a nationwide cohort study. [PDF]
ERJ Open ResYen FS +7 more
europepmc +1 more source
DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes [PDF]
, 2017 core +1 more source
Global research trends on DPP-4 inhibitors and cardiovascular outcomes: a comprehensive bibliometric analysis. [PDF]
Ann Med Surg (Lond)Amini-Salehi E +9 more
europepmc +1 more source
Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent [PDF]
, 2015 core +1 more source
DPP-4 Inhibitors as Antidiabetic Agents
Journal of Analytical & Bioanalytical Techniques, 2010 openaire +1 more source
Imeglimin and DPP-4 inhibitors: A promising therapeutic strategy for type 2 diabetes individuals with reduced insulin secretion. [PDF]
Diabetes Obes MetabHamamoto Y, Usui R.
europepmc +1 more source